Clinical use of L19IL2 and L19TNF, the recombinant fusion protein of recombinant monoclonal antibody (L19) with the human recombinant interleukin-2 (IL-2) or the human tumor necrosis factor-alpha in patients suffering from metastatic melanoma is ongoing (ClinicalTrials.gov Identifier: NCT02076633). Here, IL2 is linked to metastatic melanoma.